Table 6.
Ongoing lenalidomide-based regime trials.
Name | Phase | Age | Histology | Drugs | Status |
---|---|---|---|---|---|
NCT01415752 | II | >60 ys | Untreated MCL | RBV + RL | Ongoing and recruiting |
NCT01316523 | II | >18 ys | Untreated indolent NHL | RL | Ongoing and recruiting |
NCT00695786 | II | >18 ys | Untreated indolent NHL | RL | Ongoing and recruiting |
FIL R2-B | II | >18 ys | Untreated indolent NHL | RBL | Ongoing and recruiting |
RBV: rituximab, bendamustine, bortezomib; RL: rituximab, lenalidomide; RBL: rituximab, bendamustine, lenalidomide.